ClinicalTrials.gg
RecruitingNCT06669117Updated Jul 2, 2025

FIH Trial of VERT-002 in Patients With Locally Advanced or Metastatic Solid Tumors With MET Alterations

A Phase 1/2 interventional study of VERT-002 in Solid Tumor and MET Alteration, sponsored by Pierre Fabre Medicament. Recruiting at 19 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Pierre Fabre Medicament (part of Pierre Fabre) · Phase 1/2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2024; still recruiting 2 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
140
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France — 170 open to participants now, 327 under way, 105 of them phase 3. Carcinoma, Non-Small-Cell Lung · France.

Planned enrollment
463rd of 762
140 · median 190
Started
2024
with 62 others
Phase 1/2
81 of 875
28 open now
Primary completion
2030-10
later than 297 of 326 live
Registered
777th of 875
by date

Among the 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France, this one is the 463rd largest by planned enrollment of the 762 interventional ones that give a count, is one of 63 that started in 2024, is one of 81 in phase 1/2, reaches primary completion later than 297 of the 326 other live ones, and was the 777th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

170 of the 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France are open now. Recruiting first, the newest first:

165 more — sign in →

All 170 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 875 studies in Carcinoma, Non-Small-Cell Lung with a site in France, or all of them as a file.
02

Study summary

The goal of this clinical trial is to investigate the safety, the activity of VERT-002 (PFL-002), and the optimal safe dose to be used, in participants with solid tumors including non-small cell lung cancer.

03

Conditions studied

  • Solid Tumor
  • MET Alteration

Keywords

  • Locally advanced or metastatic solid tumors
  • MET alteration
  • Non-small cell lung cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Part 1: histological confirmation of locally advanced or solid tumor for which no standard of care treatment is available.
  2. Part 2: histological confirmation of locally advanced or metastatic NSCLC Stage IIIB/C or IV (American Joint Commission on Cancer [AJCC] 8th edition) in participants who are not eligible for or should have received available standard of care therapies including curative intent surgery, chemoradiation, radiotherapy or systemic therapy.
  3. Part 1: presence of at least one of the following MET alterations based on local documentation of blood or archived tissue results:

    • METex14 mutation
    • MET kinase domain activating gene mutations (e.g. H1094L/R/Y, D1228H/N/V, Y1230A/C/D/H)
    • MET amplification
  4. Part 2-a: presence of METex14 mutation (based on local documentation of blood or archived tissue results) and for Part 2-b presence of at least one of the following MET alterations: METex14 mutation (based on local documentation of blood or archived tissue results), de novo MET amplification (based on local documentation of archived tissue results). Confirmation after enrollment in the trial will be performed by central testing from an archival tumor sample (either tissue block or at least 15 serial cut unstained slides of 5 μm, at least 20% tumor content). In case no archival biopsy is available for central testing, the patient must be willing to have a fresh tumor biopsy sample collected and the tumor biopsy should be deemed safe and feasible by the investigator.
  5. Part 2: at least one measurable target lesion according to v1.1.
  6. (ECOG) performance status 0 or 1.
  7. Part 1: participants may have received MET Tyrosine Kinase Inhibitor (TKI) as part of previous treatment, regardless of the (first or second line), and regardless of the MET TKI being combined or not. Note: crizotinib will be considered a MET TKI.
  8. Part 2: a maximum of 3 prior lines of systemic therapies.
  9. Adequate hematologic function.
  10. Adequate hepatic function.
  11. Adequate renal function.
  12. Albumin ≥ 3 g/dL.
  13. Adequate coagulation function.
  14. Adequate cardiac function.
  15. Female participants of must have a negative highly sensitive serum β-HCG test performed within 7 days prior to the first dose of VERT-002 and a negative urine pregnancy test performed at C1D1 prior to the first dose of VERT-002.
  16. Male participants/partners with female spouse/partners of childbearing potential must agree to take appropriate precautions to avoid fathering a child.

NOTE: Other protocol defined inclusion criteria may apply.

Exclusion criteria

Exclusion Criteria:

  1. Part 2: Documented evidence by local testing of targetable oncogene driver mutations.
  2. History of a primary other than the cancer under trial (as defined for Parts 1 and 2) with the exception of:

    • Participants with a previous malignancy who completed their anticancer treatment at least 2 years before signing and with no evidence of residual disease from the prior malignancy at screening.
    • Malignancies with a negligible risk of or death (i.e. 5-year overall survival rate > 90%) that are adequately treated.
  3. Uncontrolled Central Nervous System (CNS) metastases or spinal cord compression that are associated with progressive neurological symptoms or require increasing doses of to control the CNS disease.
  4. History of to active or inactive ingredients of VERT-002, or drugs with a similar chemical structure or from a similar class.
  5. Active, bacterial, fungal, or viral infection, within 2 weeks prior to the first dose of VERT-002 (C1D1).
  6. Positive SARs-CoV-2 or variants of SARs-CoV2 test within 2 weeks prior to first dose administration of VERT-002 (C1D1) or with suspected infection with SARs-CoV-2 or variants of SARs-CoV-2 and confirmation pending.
  7. Impaired cardiovascular function or cardiovascular disease (either active or within 6 months prior to signing main informed consent).
  8. Uncontrolled intercurrent illness including, but not limited to psychiatric illness or social situation that would limit compliance with trial requirements.
  9. Past medical history of Interstitial Lung Disease (ILD), drug induced ILD, radiation pneumonitis that requires steroid treatment, or any evidence of clinically active ILD.
  10. Women who are pregnant or breastfeeding.
  11. Prior anticancer therapy:

    • MET TKI within 7 days prior to the first dose of VERT-002,
    • Any other systemic anticancer therapy within 28 days or 5 half-lives of the anticancer therapy whichever is the shortest, but with a minimum of 14 days interval, prior to the first dose of VERT-002 (C1D1),
    • Radiotherapy to a large field or including a vital organ (including whole brain radiotherapy or stereotactic radiosurgery to brain) within 14 days prior to the first dose of VERT-002 (C1D1).
  12. within 28 days prior to the first dose of VERT-002 (C1D1).
  13. Any toxicities from prior therapy with NCI- Grade > 1 at the time of the first dose administration of VERT-002 (C1D1). Exceptions include any grade alopecia, fatigue and peripheral neuropathy with a grade ≤ 2.
  14. Major surgical procedure within 14 days of the first dose of VERT-002 (C1D1).
  15. Participation in a clinical trial with administration of an drug within 5 half- lives plus 14 days of the investigational drug, prior to the first dose of VERT-002 (C1D1).

NOTE: Other protocol defined exclusion criteria may apply.

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    VERT-002 (PFL-002)

    Part 1: Dose escalation (Phase Ia): VERT-002 will be administered via intravenous (IV) infusion every 2 weeks. 4 provisional doses are planned. An alternative regimen may be tested informed by the emerging data Part 2a: Preliminary Activity Assessment (Phase Ib): One dose \& schedule selected from Part 1 Part 2b: Dose range optimization (Phase Ib): 2 or 3 doses \& schedule selected from Part 1: From the lower limit \[Optimal Biologically Active Dose (OBD)\] \& upper limit \[Maximum Tolerated Dose (MTD) or Maximum Administered Dose (MAD) if MTD is not reached\] Part 3: Dose Expansion at RP2D (Phase II): To be defined later on

    Drug: VERT-002

Interventions

  • DrugVERT-002

    Route of Administration: Intravenous

    Also known as: PFL-002

06

What researchers measure

Primary outcomes

  1. Safety: All parts: Incidence and severity of treatment emergent adverse events (TEAEs)/serious adverse events (SAEs), according to NCI-CTCAE v5.0 criteria.

    Time frame: Screening to Safety Follow-up (30 days post last dose)

  2. Tolerability: All parts: Incidence of TEAEs/SAEs leading to VERT-002 dose reduction, interruption or discontinuation.

    Time frame: From screening up to 13 months

  3. Part 1: Maximum Tolerated Dose (MTD): Incidence of Dose-Limiting Toxicities (DLTs)

    Time frame: From the start of trial treatment until end of Cycle 1 per dose level

  4. Part 1: Optimal Biologically Active Dose (OBD): Incidence on PK/PD and ORR (Objective Response Rate)

    Time frame: From the first VERT-002 intake up to 13 months

  5. Part2a: Preliminary activity assessment: ORR and cORR (Confirmed Objective Response Rate)

    Time frame: From the start of trial treatment up to 13 months

  6. Part2b: Recommended Phase 2 Dose (RP2D): Incidence on overall safety, PK, PDs and cORR

    Time frame: From the start of trial treatment up to 13 months

Secondary outcomes

  1. Serum PK Parameter: Maximum Plasma Concentration (Cmax)

    Time frame: Part 1: Cycle 1 and Cycle 2 - Days 1,2,4,8,15 and 22; Cycle 3 onward Day 1 and EOT (up to 8 months). Part 2: Cycle 1 Days 1,8 and 15; Cycle 2 Days 1 and 15; Cycle 3 onward Day 1; and EOT (up to 12 months). Each cycle is 28 Days

  2. Serum PK Parameter: PK exposure parameter: Area Under The Plasma Concentration-Time Curve From Time Zero To Dosing Interval (AUC0-tau)

    Time frame: Part 1: Cycle 1 and Cycle 2 - Days 1,2,4,8,15 and 22; Cycle 3 onward Day 1 and EOT (up to 8 months). Part 2: Cycle 1 Days 1,8 and 15; Cycle 2 Days 1 and 15; Cycle 3 onward Day 1; and EOT (up to 12 months). Each cycle is 28 Days

  3. Serum PK Parameter: Accumulation Ratio (Rac) for Maximum Observed Concentration (Cmax) and Area Under The Concentration-Time Curve (AUC)

    Time frame: Part 1: Cycle 1 and Cycle 2 - Days 1,2,4,8,15 and 22; Cycle 3 onward Day 1 and EOT (up to 8 months). Part 2: Cycle 1 Days 1,8 and 15; Cycle 2 Days 1 and 15; Cycle 3 onward Day 1; and EOT (up to 12 months). Each cycle is 28 Days

  4. Serum PK Parameter: Trough Concentration (Ctrough)

    Time frame: Part 1: Cycle 1 and Cycle 2 - Days 1,2,4,8,15 and 22; Cycle 3 onward Day 1 and EOT (up to 8 months). Part 2: Cycle 1 Days 1,8 and 15; Cycle 2 Days 1 and 15; Cycle 3 onward Day 1; and EOT (up to 12 months). Each cycle is 28 Days

  5. Serum ADA Parameter: Incidence of VERT-002 anti- drug antibodies (ADA)

    Time frame: Parts 1 and 2: Cycle 1 Days 1,8, and 15; Cycle 2 Days 1 and 15; Cycle 3 onward Day 1; and EOT (up to 8 months). Each cycle is 28 Days

  6. All Parts: cORR (Confirmed Objective Response Rate) based on Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 per Investigator's Reviewer (IR)

    Time frame: From the start of the treatment to at least 80% of the participants have been followed up for 24 months

  7. All Parts: DCR (Disease Control Rate) based on RECIST version 1.1 per IR

    Time frame: From the start of the treatment to at least 80% of the participants have been followed up for 24 months

  8. All Parts: TTR (Time To Response) according to RECIST version 1.1 per IR

    Time frame: From the start of the treatment to at least 80% of the participants have been followed up for 24 months

  9. All Parts: Duration Of Response (DOR) according to RECIST v1.1 per IR

    Time frame: From the start of the treatment to at least 80% of the participants have been followed up for 24 months

  10. Part 2: Progression Free Survival (PFS) according to RECIST v1.1 per IR

    Time frame: From the start of the treatment to at least 80% of the participants have been followed up for 24 months

  11. Part 2: Overall Survival (OS)

    Time frame: From the start of the treatment to at least 80% of the participants have been followed up for 24 months

07

Study locations

19 of 19 sites recruiting
  • Georgetown Lombardi Comprehensive Cancer Center
    Washington D.C., District of Columbia 20007, United States
    Recruiting
    • Chul Kim, MD · Principal investigator
  • Gabrail Cancer Research Center
    Canton, Ohio 44718, United States
    Recruiting
    • Nashat Gabrail, MD · Principal investigator
  • Sarah Cannon Research Institute Oncology Partners
    Nashville, Tennessee 37203, United States
    Recruiting
    • Meredith Ann McKean, MD, MPH · Principal investigator
  • Institut Jules Bordet
    Anderlecht, 1070, Belgium
    Recruiting
  • APHP de Marseille - Hôpital Nord
    Marseille, 13915, France
    Recruiting
    • Laurent Greillier · Principal investigator
  • Institut de Cancerologie de Ouest (ICO) - Saint-Herblain
    Saint-Herblain, 44805, France
    Recruiting
    • Judith Raimbourg · Principal investigator
  • Institut Universitaire du Cancer de Toulouse - Oncopole
    Toulouse, 31100, France
    Recruiting
    • Julien Mazieres · Principal investigator
  • Gustave Roussy
    Villejuif, 94805, France
    Recruiting
  • Universitaet zu Koeln - Centrum fuer Integrierte Onkologie (CIO)
    Cologne, 45147, Germany
    Recruiting
  • Universitätsklinikum Carl Gustav Carus Dresden
    Dresden, 1307, Germany
    Recruiting
    • Martin Wermke · Principal investigator
  • Azienda Ospedaliero - Universitaria San Luigi Gonzaga
    Orbassano, 10043, Italy
    Recruiting
    • Silvia Novello · Principal investigator
  • Nederlands Kanker Instituut - Antoni van Leeuwenhoek Ziekenhuis
    Amsterdam, 1066 CX, Netherlands
    Recruiting
    • Gerrina Ruiter, MD, PhD · Principal investigator
  • Yonsei University College of Medicine
    Seoul, 03722, South Korea
    Recruiting
    • Sun Min Lim, MD, PhD · Principal investigator
  • Asan Medical Center (AMC)
    Seoul, 05505, South Korea
    Recruiting
    • Dae Ho Lee, MD, PhD · Principal investigator
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Recruiting
    • Luis Paz-Ares Rodriguez, MD, PhD · Principal investigator
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    Recruiting
    • Francisco Javier de Castro Carpe · Principal investigator
  • National Taiwan University Hospital
    Taipei, 100225, Taiwan
    Recruiting
    • Chia-Chi Lin, MD, PhD · Principal investigator
  • Taipei Medical University Hospital
    Taipei, 110, Taiwan
    Recruiting
    • Chao-Hua Chiu, MD · Principal investigator
  • Taipei Veterans General Hospital
    Taipei, 11217, Taiwan
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Pierre Fabre is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies as defined in our commitments. These requests are reviewed and approved by an independent review panel on the basis of scientific ground. All data provided if any is anonymized to respect the privacy of trial participants in line with applicable laws and regulations.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: This trial data availability is according to the criteria and process described on our website.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2024 (actual). Primary completion is estimated for Oct 2030, 71 months after the start.

Of 312 industry-sponsored phase 1/2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 59 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 77. This study's planned 71 months is above that.

Counting every sponsor, half of 436 studies reached it within 63 months; a quarter within 41 and three quarters within 80.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 24, 2024
First posted
Nov 1, 2024
StartActual
Oct 22, 2024
Primary completionEst.
Oct 21, 2030
CompletionEst.
Oct 1, 2032
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06669117
Responsible party
Sponsor
First posted
Nov 1, 2024
Start date
Oct 22, 2024
Primary completion
Oct 21, 2030 (estimated)
Completion
Oct 1, 2032 (estimated)
Last update
Jul 2, 2025

Study contacts

Medical Officer
Contact
yuhua.wang@pierre-fabre.com
+33 684 66 43 48

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion